Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1
gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other
places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.